Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
Conditions: Relapsing Remitting Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Primary Progressive Multiple Sclerosis Interventions: Drug: Rituximab; Drug: Ocrelizumab; Drug: Fexofenadine; Drug: Paracetamol; Drug: Methylprednisolone Sponsors: Rigshospitalet, Denmark; Odense University Hospital; Aarhus University Hospital; Aalborg University Hospital; Herlev Hospital; Hillerod Hospital, Denmark; Zealand University Hospital; Kolding Sygehus; Regional Hospital Holstebro; Hvidovre University Ho spital; Hospital of South West Jutland, Esbjerg, Denmark; GCP unit, Copenhagen University Hospital; GCP-unit at Aarhus University Hospital, Aarhus, Denmark; Hospital of Southern Jutland, Sønderborg, Denmark; Hospital of Central Denmark Region, Viborg, Denmark; Dansk e Regioner; GCP unit Odense University Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allegra | Denmark Health | Fexofenadine | Hospitals | Methylprednisolone | Multiple Sclerosis | Research | Rituxan | Study